Skip to main navigation Skip to search Skip to main content

A phase 2b multicenter randomized open-label assessor blinded superiority study to compare the efficacy and safety of dalbavancin to standard of care antibiotic therapy for the completion of treatment of patients with

Upstate Medical University

Project: Research

Project Details

StatusActive
Effective start/end date12/1/20 → 11/30/26

Funding

  • National Institute of Allergy & Infectious Disease: $20,750.00